Log in

NYSEARCA:CNCR - Loncar Cancer Immunotherapy ETF Stock Price, Forecast & News

$23.55
+0.15 (+0.64 %)
(As of 12/6/2019 04:00 PM ET)
Add
Today's Range
$23.52
Now: $23.55
$23.69
50-Day Range
$18.46
MA: $21.01
$23.61
52-Week Range
$16.87
Now: $23.55
$23.78
Volume8,387 shs
Average Volume9,843 shs
Market Capitalization$38.85 million
P/E RatioN/A
Dividend Yield0.00%
BetaN/A

Basic Details

Issuer Exchange Traded Concepts
Fund NameLoncar Cancer Immunotherapy ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:CNCR
Inception Date10/13/2015
Fund ManagerDenise M. Krisko
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkLoncar Cancer Immunotherapy Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$38.63 million
Average Daily Volume$11,514.90
Discount/Premium1,995.59%

ETF Expenses

Management Fee0.79%
Other Expenses0.00%
Total Expenses0.79%
Fee Waiver0.00%
Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorExchange Traded Concepts, LLC
CustodianU.S. Bank National Association
DistributorQuasar Distributors, LLC
Transfer AgentU.S. Bancorp Fund Services, LLC
Trustee
Lead Market MakerJane Street

Receive CNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCR and its competitors with MarketBeat's FREE daily newsletter.


Geographic Exposure of Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR)
Currency Exposure of Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR)
Sector Exposure of Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR)
Industry Exposure of Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR)

Loncar Cancer Immunotherapy ETF (NYSEARCA:CNCR) Frequently Asked Questions

What is Loncar Cancer Immunotherapy ETF's stock symbol?

Loncar Cancer Immunotherapy ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "CNCR."

Has Loncar Cancer Immunotherapy ETF been receiving favorable news coverage?

Media headlines about CNCR stock have trended extremely negative on Saturday, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Loncar Cancer Immunotherapy ETF earned a daily sentiment score of -4.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near future. View News Stories for Loncar Cancer Immunotherapy ETF.

How do I buy shares of Loncar Cancer Immunotherapy ETF?

Shares of CNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Loncar Cancer Immunotherapy ETF's stock price today?

One share of CNCR stock can currently be purchased for approximately $23.55.

How big of a company is Loncar Cancer Immunotherapy ETF?

Loncar Cancer Immunotherapy ETF has a market capitalization of $38.85 million. View Additional Information About Loncar Cancer Immunotherapy ETF.


MarketBeat Community Rating for Loncar Cancer Immunotherapy ETF (NYSEARCA CNCR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Loncar Cancer Immunotherapy ETF and other stocks. Vote "Outperform" if you believe CNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: volatile stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel